Calquence and Imbruvica are both Bruton's tyrosine kinase (BTK) inhibitors used to treat certain types of lymphoma and chronic lymphocytic leukemia (CLL). While they share a similar mechanism of action, they have different side effect profiles [1].
What are the common side effects of Calquence?
The most common side effects reported with Calquence (acalabrutinib) include diarrhea, fatigue, muscle aches, and rash [1]. Less frequently, patients may experience nausea, headache, and cough [2].
What are the common side effects of Imbruvica?
Imbruvica (ibrutinib) has a broader range of frequently reported side effects. These include diarrhea, fatigue, bruising, shortness of breath, decreased platelet count (thrombocytopenia), and upper respiratory tract infections [1]. Other common adverse events can involve nausea, rash, joint pain, and anemia [3].
How do Calquence and Imbruvica side effects compare?
While both drugs can cause fatigue and diarrhea, Imbruvica is associated with a higher incidence of bleeding events, such as bruising, and cardiac issues, including atrial fibrillation. Calquence has shown a lower rate of these particular cardiovascular and bleeding side effects compared to Imbruvica in some studies [1][4].
What are the risks of bleeding with Imbruvica?
Imbruvica carries a risk of serious bleeding events, which can be life-threatening. These can range from minor bruising and nosebleeds to more severe hemorrhages in the brain or gastrointestinal tract [5]. Patients on Imbruvica may need dose adjustments or interruption of treatment if significant bleeding occurs [3].
What are the risks of heart problems with Imbruvica?
Heart rhythm abnormalities, particularly atrial fibrillation and atrial flutter, are known side effects of Imbruvica. These can increase the risk of stroke and require close monitoring and management by a healthcare provider [5].
How does Calquence compare in terms of cardiovascular and bleeding risks?
Calquence generally demonstrates a lower incidence of atrial fibrillation and major bleeding events compared to Imbruvica. This difference has been observed in clinical trials and real-world data, making Calquence a potential alternative for patients who are at higher risk for these specific side effects [4][1].
What other side effects are associated with these drugs?
Both medications can cause infections due to their impact on the immune system. Additionally, patients may experience low blood cell counts, including a decrease in white blood cells, platelets, and red blood cells [2][3]. Calquence can also lead to headache and muscle pain [2].
How do doctors monitor for side effects?
Healthcare providers monitor patients for side effects through regular physical examinations, blood tests to check blood cell counts, and assessment of symptoms. Patients are advised to report any new or worsening symptoms, such as unusual bleeding, heart palpitations, shortness of breath, or severe diarrhea, to their doctor promptly [5][2].
Are there interactions with other medications?
Both Calquence and Imbruvica can interact with other drugs, potentially altering their effectiveness or increasing the risk of side effects. It is crucial for patients to inform their doctor about all medications, including over-the-counter drugs and supplements, they are taking [5][2].
Sources:
[1] https://www.drugpatentwatch.com/news/calquence-vs-imbruvica-side-effects
[2] https://www.drugpatentwatch.com/news/calquence-side-effects
[3] https://www.drugpatentwatch.com/news/imbruvica-side-effects
[4] https://www.drugpatentwatch.com/news/calquence-vs-imbruvica-efficacy-and-safety-profile
[5] https://www.drugpatentwatch.com/news/managing-imbruvica-side-effects